BRIEF-翰森制药称奥莱泊肽注射液上市许可申请获国家药品监督管理局受理

路透中文

06/04

BRIEF-<a href="https://laohu8.com/S/03692">翰森制药</a>称奥莱泊肽注射液上市许可申请获国家药品监督管理局受理

路透北京6月4日 - Hansoh Pharmaceutical Group Company Ltd 3692.HK：

* 本集团创新药奥莱泊肽注射液上市许可申请(NDA)获中国国家药品监督管理局(NMPA)受理，适用于肥胖或超重成人的长期体重管理

* 奥莱泊肽是一款本集团自主研发的每周一次给药胰高血糖素样肽-1(GLP-1)╱葡萄糖依赖性促胰岛素多肽(GIP)双受体激动剂（完）

公告全文，请点击此处

(发稿刘珞焱)

((luoyan.liu@tr.com; +86 021 2083 0166;))

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2640805281"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2640805281\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2640805281?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-06-04 07:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640805281","market":"hk","top_or_hot":-1,"title":"BRIEF-翰森制药称奥莱泊肽注射液上市许可申请获国家药品监督管理局受理","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/03692\">翰森制药</a>称奥莱泊肽注射液上市许可申请获国家药品监督管理局受理</title></head><body><p><span>路透北京6月4日</span><span> - </span>Hansoh Pharmaceutical Group Company Ltd <span>3692.HK</span>：</p><p>* 本集团创新药奥莱泊肽注射液上市许可申请(NDA)获中国国家药品监督管理局(NMPA)受理，适用于肥胖或超重成人的长期体重管理</p><p>* 奥莱泊肽是一款本集团自主研发的每周一次给药胰高血糖素样肽-1(GLP-1)╱葡萄糖依赖性促胰岛素多肽(GIP)双受体激动剂（完）</p><p>公告全文，请点击此处</p><p> (发稿 刘珞焱)</p><p> ((luoyan.liu@tr.com; +86 021 2083 0166;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-翰森制药称奥莱泊肽注射液上市许可申请获国家药品监督管理局受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-翰森制药称奥莱泊肽注射液上市许可申请获国家药品监督管理局受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-06-04 07:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/03692\">翰森制药</a>称奥莱泊肽注射液上市许可申请获国家药品监督管理局受理</title></head><body><p><span>路透北京6月4日</span><span> - </span>Hansoh Pharmaceutical Group Company Ltd <span>3692.HK</span>：</p><p>* 本集团创新药奥莱泊肽注射液上市许可申请(NDA)获中国国家药品监督管理局(NMPA)受理，适用于肥胖或超重成人的长期体重管理</p><p>* 奥莱泊肽是一款本集团自主研发的每周一次给药胰高血糖素样肽-1(GLP-1)╱葡萄糖依赖性促胰岛素多肽(GIP)双受体激动剂（完）</p><p>公告全文，请点击此处</p><p> (发稿 刘珞焱)</p><p> ((luoyan.liu@tr.com; +86 021 2083 0166;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nL4S42B22Y:1","article_id":"2640805281","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640805281","pubTimestamp":1780530016,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-翰森制药称奥莱泊肽注射液上市许可申请获国家药品监督管理局受理路透北京6月4日 - Hansoh Pharmaceutical Group Company Ltd 3692.HK：* 本集团创新药奥莱泊肽注射液上市许可申请(NDA)获中国国家药品监督管理局(NMPA)受理，适用于肥胖或超重成人的长期体重管理* 奥莱泊肽是一款本集团自主研发的每周一次给药胰高血糖素样肽-1(GLP-1)╱葡萄糖依赖性促胰岛素多肽(GIP)双受体激动剂（完）公告全文，请点击此处 (发稿 刘珞焱) ((luoyan.liu@tr.com; +86 021 2083 0166;))","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"03692":"翰森制药","BK1191":"制药","BK1583":"高瓴概念","BK1589":"北水核心资产"},"translate_title":"BRIEF-Hansen Pharmaceuticals says the marketing authorization application for olepotide injection was accepted by the National Medical Products Administration","themeId":"37684715aaf54a73b9fe52ee56a263cc","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9},"content_text":"BRIEF-翰森制药称奥莱泊肽注射液上市许可申请获国家药品监督管理局受理路透北京6月4日 - Hansoh Pharmaceutical Group Company Ltd 3692.HK：* 本集团创新药奥莱泊肽注射液上市许可申请(NDA)获中国国家药品监督管理局(NMPA)受理，适用于肥胖或超重成人的长期体重管理* 奥莱泊肽是一款本集团自主研发的每周一次给药胰高血糖素样肽-1(GLP-1)╱葡萄糖依赖性促胰岛素多肽(GIP)双受体激动剂（完）公告全文，请点击此处 (发稿 刘珞焱) ((luoyan.liu@tr.com; +86 021 2083 0166;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}